Kornimate/medical-research-clean huggingface dataset:
simultaneous multinuclear metabolic mri in newly diagnosed or recurrent glioma

Conditions: Glioma; Malignant Glioma; Recurrent Glioma; Recurrent Malignant Glioma

Summary: this clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (mri) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). this trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

primary objectives: i. construct and test a novel multinuclear na+-h+ metabolic mri sequence with sensitivity to sodium (na+) concentration, potential of hydrogen (ph), and oxygen (o2). ii. correlate na+-, ph-, and o2-weighted mr image measurements with sodium-proton exchanger isoform-1 (nhe1) immunohistochemistry (ihc), bioenergetics, and gene expression using stereotactic image-guided biopsies from human brain tumors. iii. quantify changes in na+-, ph-, and o2-weighted mr images after neoadjuvant anti-pd-1 immunotherapy in recurrent glioblastoma (gbm) and explore associated changes in tumor biology. outline: aim 1: previous scan data from healthy subjects is collected and analyzed. aim 2: patients undergo mri. patients also undergo collection of tissue samples for ihc analysis. aim 3: patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.

Eligibility criteria:
inclusion criteria: * aim 1: healthy volunteers with no evidence of brain tumors or neurologic disease * aim 1: age 18+ * aim 2: newly diagnosed or recurrent suspected or confirmed glioma (low or high grade) * aim 2: 10 idh mutant and 10 idh wild type gliomas * aim 2: clinically indicated for resective surgery or biopsy * aim 2: age 18+ * aim 2: tumor size \> 1x1x1 cm (measurable) * aim 3: recurrent glioma enrolled in an immunotherapy trial or clinically indicated to receive immunotherapy including anti-pd1 * aim 3: age 18+ exclusion criteria: * aim 1: cannot safely perform an mri * aim 1: age \< 18 * aim 2: cannot safely perform an mri or use of mri contrast agents * aim 2: age \< 18 * aim 3: cannot safely perform an mri or use of mri contrast agents * aim 3: age \< 18
symphony il-6 cutoff validation study for patients at risk of severe sepsis

Conditions: Severe Sepsis

Summary: symphony il-6 is a device that quantitates human il-6 by fluorescence enzyme immunoassay (feia) from whole-blood specimens. use of symphony il- 6 removes the need for plasma separation before testing. symphony il-6 comprises two components, the symphony fluorescence immunoanalyzer and the symphony il-6 cartridge. whole blood is added to the cartridge and then up to six cartridges can be inserted into the immunoanalyzer. after 20 minutes a readout and printout are given with a quantitative il-6 concentration. the used cartridges are fully enclosed and can be easily disposed of in general hospital bio-waste. given the nature of this device and its portability, there is potential for future deployment as a point-of-care (poc) device. this study is to validate an interleukin-6 (il-6) cutoff value using the symphony il-6 test for patients at high risk of severe sepsis caused by a covid-19 infection


Eligibility criteria:
inclusion criteria: * whole blood specimen collected in edta anticoagulant tubes * subject is considered to have severe or critical illness per below: severe illness 1. spo2 \< 94% on room air at sea level; 2. ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (pao2/fio2) \< 300 mmhg; 3. respiratory frequency \> 30 breaths/min; 4. or lung infiltrates \>50% critical illness a) respiratory failure; b) septic shock; c) and/or multiple organ dysfunction d) at least one criteria of severe illness * subject confirmed to be covid-19 positive by an eua rt-pcr test * subject is 18+ years of age * minimum volume of 100µl for symphony il-6 testing * specimen is available for testing within 12 hours from collection exclusion criteria: * subject is receiving an anti-il-6 treatment * subject is receiving corticosteroids * hemolyzed specimens
longitudinal evaluation of hiv-associated lung disease phenotypes

Conditions: Chronic Obstructive Pulmonary Disease; HIV; Emphysema

Summary: the overall hypotheses of this proposal are that discrete phenotypes of hiv chronic obstructive pulmonary disease (copd) differ in their trajectories, biomarkers, and risk factors and that persistent viral infection including residual hiv is linked to hiv copd.

the study is a multicenter, prospective observational study of pathogenesis of hiv pulmonary disease. we will determine the prevalence and risk factors for lung dysfunction as quantified by pulmonary function testing in hiv+ subjects. we will build on our existing longitudinal cohorts while adjusting for important co-variates such as antiretroviral therapy (art), smoking history, co-infections, and illicit drug use. evaluations will be scheduled at baseline, 18 months, and 36 months. (6, 12, 18 and 36 months for art initiators at the ucsf). study visits will consist of blood draw, questionnaires, pulmonary function testing, 6-minute walk test, ct of the chest at visit two. oral specimen collection and glycocalyx and echocardiogram (visit two) at the pittsburgh site only.

Eligibility criteria:
inclusion criteria: * hiv-1 infection, documented in medical record at any time prior to study entry. * men and women age 18 to 80. * ability and willingness to complete all tests. * participant in hlrc studies, macs, women's interagency health study, and local hiv clinics. * for ucsf only, new art initiators from women's interagency health study or the hiv clinic exclusion criteria: * pregnancy or breast-feeding. * contraindication to pulmonary function testing (i.e. abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.). * increasing respiratory symptoms or febrile (temperature \>100.40f \[380c\]) within 4 weeks of study entry. * hospitalization within 4 weeks prior to study entry (excluding mental health). * uncontrolled hypertension at screening visit (systolic \> 180 mm hg or diastolic \> 100 mm hg) from an average of two or more readings. subject may return for screening after blood pressure is controlled. * active cancer requiring systemic chemotherapy or radiation. * active infection of lungs, brain, or abdomen. * intravenous drug use or alcohol use that will impair ability to complete study investigations in the opinion of the investigator

Keywords: antiretroviral therapy pulmonary function biomarkers
trial to reduce hospitalizations in children with medical complexity

Conditions: Chronic Illness

Summary: the investigators hypothesize that an intervention, within an established patient-centered medical home, aimed at reducing modifiable risks for hospitalization, can decrease hospital utilization among medically complex children.

the investigators will pilot test an intervention that includes contingency planning and care transitions within an established medical home program caring for children with medical complexity. children with medical complexity receiving care within the ucla medical home program will be randomized to the pilot intervention or usual medical home care. the primary goal will be to reduce admissions and readmissions in the intervention group.

Eligibility criteria:
inclusion criteria: * children ages 0 to 17 years old who are enrolled in the pediatric medical home program at ucla * english and spanish-speaking only exclusion criteria: * children older than 17 years old who are enrolled in the pediatric medical home program * non-english and non-spanish speakers

Keywords: hospitalization readmissions medical complexity
a study to determine the inter/intra observer and intra-subject variability of whole blood clotting time measurements

Conditions: Healthy

Summary: the purpose of the study is to characterize the distribution and sources of variability in whole blood clotting time (wbct) measurements in human blood collected from healthy volunteers by 5 different technicians.

no investigational product was administered to any subject in this study.

Eligibility criteria:
inclusion criteria: 1. signed and dated, written informed consent (institutional review board \[irb\]-approved informed consent form \[icf\]). 2. healthy male and female subjects aged 18 to 65 years (inclusive) with suitable veins for venipuncture. (healthy as determined by medical history) exclusion criteria: 1. healthy subjects who do not conform to the above inclusion criteria. 2. healthy subjects who cannot communicate reliably with the investigator. 3. history of major bleeding or major trauma within the past 6 months 4. healthy volunteer with a propensity to bleed (i.e. due to recent trauma, recent surgery, peptic ulcer, active or recent gastrointestinal bleeding or bleeding from hemorrhoids). 5. significant infection or known inflammatory process within 2 weeks of screening. 6. treatment with any investigational products or therapies within 30 days (or 5 half lives, whichever is greater) prior to screening. 7. received non-steroidal anti-inflammatory (nsaid) or medications (including any type of anticoagulant or aspirin \[asa\]) with a direct effect on hemostasis within 7 days of testing 8. unwillingness or inability to comply with procedures required in this protocol. 9. subjects who are concurrently enrolled in any other clinical study.

Keywords: whole blood clotting time
safety and efficacy of folatescan (technetium tc 99m ec20) in subjects with pituitary tumors

Conditions: Pituitary Tumors

Summary: many types of cancers overexpress a receptor for the vitamin folate (folate receptor). this phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (ec20) designed to bind to the folate receptor. the study is designed as an open-label, baseline-controlled study.

this is a phase 2 open-label, single-treatment group, baseline-controlled study designed to verify product safety, gather data on the percentage of subjects with pituitary tumors with increased uptake of folatescan in tumors and correlate the immunohistochemical staining findings with the folatescan images, in subjects with pituitary tumors.

Eligibility criteria:
inclusion criteria: subjects must meet the following eligibility requirements to be enrolled in the study: 1. subject must be 18 years of age or older. 2. subject must have a pituitary tumor. 3. subject must have good kidney function. 3. subject must provide written informed consent prior to enrollment. exclusion criteria: subjects must be excluded if any of the following conditions are present: 1. subject is pregnant or breastfeeding. 2. subject is simultaneously participating in another investigational drug study. 3. subject has completed the follow-up phase of any previous study loess than 30 days prior to enrollment in this study. 4. subject is unable to tolerate conditions for radionuclide imaging. 5. subject has been administered another radiopharmaceutical that would interfere with the assessment of technetium tc 99m ec20.

Keywords: pituitary tumors
forxiga tablets specific clinical experience investigation for elderly

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of the investigation is to confirm the following under the post-marketing actual use of forxiga tablets (hereinafter referred to as forxiga) in elderly patients. * development of adrs specified as key investigation items and the risk factors * contributing factors possibly having an impact on the safety and efficacy * development of adrs unexpected from the precautions for use and adrs under actual drug use


Eligibility criteria:
inclusion criteria: patients treated with forxiga for the first time during three months after the launch due to type 2 diabetes mellitus, which is the indication of the drug, aged 65 or over at the time when forxiga was started. in addition, patients receiving the study drug of forxiga before the launch should be included also. exclusion criteria: n/a

Keywords: type 2 diabetes mellitus diabetes forxiga elderly
treatment outcomes and patient satisfaction of oral lichen planus treatment

Conditions: Erosive Oral Lichen Planus; Atrophic Lichen Planus

Summary: the goal of this clinical trial is to assess honey in orabase (1:1) for treating patients with olp and improving their quality of life: the research question aims to answer: does honey in orabase (1:1) improve or reduce olp symptoms compared to the standardized treatment by triamcinolone acetonide 0.1% drug and improve the patient's quality of life? participants will: take drug abc or a placebo every day for 4 months visit the clinic once every 2 weeks for checkups and tests keep a diary of their symptoms and the number of times they use a rescue inhaler

the study comprised 56 patients diagnosed with oral lichen planus, who were randomly selected according to inclusion and exclusion criteria. the subjects were between 35 and 60 years old, capable of complying with the study procedure, and provided informed consent. exclusion criteria encompassed those with alternative oral mucosal illnesses, systemic problems influencing olp or wound healing, allergies or sensitivities to honey or triamcinolone, or those receiving systemic corticosteroids or immunosuppressive drugs. individuals who were pregnant or lactating, as well as those unable to provide informed written consent, were excluded.

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of oral lichen planus * symptomatic olp lesions (erosive/atrophic) * participants are between 35 and 60 years old, who are able to adhere to the study protocol, and sign informed consent. exclusion criteria: * patients with other oral mucosal disorders, or systemic conditions influencing olp or wound healing, allergies or hypersensitivity to honey or triamcinolone * patients who administer systemic corticosteroids or immunosuppressive agents. * pregnancy or lactation * inability to comprehend or adhere to study directives * patients who are not able to sign an informed written consent
progressive muscle relaxation effect on sleep quality, depression and stress in people with multiple sclerosis

Conditions: Multiple Sclerosis; Depression; Sleep; Stress Psychological

Summary: objective: evaluate the effects of progressive muscle relaxation on sleep quality and on stress and depression levels of individuals with multiple sclerosis.

introduction: multiple sclerosis is a chronic, autoimmune disease, characterized by demyelination and neurodegeneration of the central nervous system. the progressive course of this disease may cause individuals to develop extreme dependency and create serious difficulties both to the individuals themselves and family members and caregivers, since the disease brings a number of physical, emotional, psychological and social symptoms. therefore, it is essential to offer healthcare practices that go beyond the usually fragmenting, dehumanized care services that focus on the disease bodily processes. objective: evaluate the effects of progressive muscle relaxation on sleep quality and on stress and depression levels of individuals with multiple sclerosis. methodology: this is randomized clinical test. the sample was made up of 40 individuals with multiple sclerosis (20 in control group and 20 in the experimental group) in outpatient follow-up. the progressive muscle relaxation technique was employed. in order to collect the data, we adopted the interview with form filling technique, using the pittsburgh sleep quality index, perceived stress scale and beck depression inventory. blood pressure, heart rate and respiratory rate of experimental group were measured before and after the progressive muscle relaxation intervention. in order to treat statistical data, we used statistical package for social sciences, version 19.0.

Eligibility criteria:
inclusion criteria: * to be diagnosed with multiple sclerosis for at least 6 months * to be diagnosed with relapsing-remitting multiple sclerosis * to have expanded disability status scale score \< 5.0 * to not have had any attacks during the 3-month period preceding enrollment in the study * to have audio at home * to be residing in the metropolitan region of vitória-espirito santo-brazil. * to be 18-65 years of age * treatment with an immunomodulator exclusion criteria: * being hospitalized at the time of data collection or outbreak at the time of data collection * have physical and / or mental changes that prevent the collection of data, such as motor or cognitive deficits * experiencing relapse and/or corticosteroid use within the last month, diagnosed with progressive ms (primary or secondary) * use of psychotropic drugs (antidepressants, benzodiazepines, antipsychotic and cannabis, or other stimulants), * practice of other relaxation techniques (yoga, pilates, meditation, psychotherapy)
the effectiveness of brushing and flossing sequence on control of plaque and gingival inflammation

Conditions: Gingival Inflammation; Plaque; Gingival Bleeding; Plaque Control

Summary: this study evaluates the effectiveness of brushing and flossing sequence in the control of dental plaque and gingival inflammation.

periodontal disease is the disease of the supporting dental tissues like alveolar bone,periodontal ligament cementum and gingiva. the most common form is plaque-induced gingivitis . bleeding on gingival probing is one of the hallmarks of gingival inflammation.the removal of dental plaque is the most crucial action for preventing and treating gingival inflammation. toothbrush along with toothpaste are still the most reliable means of plaque control. however, cleaning should be thorough and performed at regular intervals. toothbrush has a limited ability to reach all the areas around the tooth. inter-dental areas are prone for plaque accumulation and gingival inflammation. dental floss is one of the most effective tool in addition to tooth brush to remove inter-dental plaque. the sequence of using toothbrush and dental floss may influence the removal of dental plaque and consequently reducing the bleeding on probing of gingiva. there is conflicting evidence in the literature. the hypothesis of this study is that the sequence of brushing and flossing will not influence control of plaque control and gingival inflammation.

Eligibility criteria:
inclusion criteria: • dental students of dental school of melaka-manipal medical college exclusion criteria: * participants who had systemic diseases * gingivitis or periodontitis * use of antibiotics in the past 3 months, * pregnancy, * smoking * orthodontic appliances.

Keywords: gingiva gingivitis flossing brushing plaque control gingival bleeding bleeding point index rustogi modified navy plaque index dental plaque tooth brushing
thalidomide results in diminished ovarian reserve in reproductive age female ibd patients

Conditions: Crohn Disease

Summary: the effectiveness of thalidomide in treating inflammatory bowel disease has been widely recognized. meanwhile, many serious adverse drug reactions were notified， but no reports on ovarian reserve function.therefore, this study was to investigate the influence of thalidomide on function of ovarian reserve.

it will be divided two groups of patients according to the treatment itself . one group was treated by thalidomide, the other was other treatment excluding. it will detect the function of ovarian reserve before and after treatment in both two groups, to investigate the influence of thalidomide on function of ovarian reserve.

Eligibility criteria:
inclusion criteria: * age 18-50 years old diagnosis of patients with cd exclusion criteria: * pregnancy or lactation period of women have fertility program during the study treatment not foot eight weeks after last ifx central or peripheral nerve disease abnormal in liver and renal function heart function failure malignant tumor active tuberculosis
effect of a mobile app on improving asthma control in patients with persistent asthma

Conditions: Asthma

Summary: minspirers_rct aims to assess the magnitude of the effect of a mobile app for improving asthma control in adolescents and adults with persistent asthma, followed at primary and secondary care in portugal.

inspirers_rct is a pilot randomized, multicenter superiority clinical trial regarding the effect of a mobile app together with usual care (experimental group) in comparison to usual care alone (control group) in adolescents and adults with persistent asthma. the study includes two face-to-face visits (initial visit and at 3 months), and 3 telephone interviews (1 week, 1 month and 4 months), implemented in 32 primary (general practice) and secondary care centers (allergy, pediatrics, pulmonology) in portugal.

Eligibility criteria:
inclusion criteria: * age between 13 and 17 years (adolescents) or and between 18 and 64 years (adults); * previous medical diagnosis of persistent asthma; * uncontrolled or partially controlled asthma according to global initiative for asthma (gina) criteria; * active prescription of inhaled control medication for asthma (all treatments will be accepted. there will be no change in the prescribed therapeutic regimen directly or indirectly related to participation in this study); * ability to use mobile app and a access (availability and use) to android mobile devices with internet access; * do not currently use any mobile application for asthma management. exclusion criteria: * patients diagnosed with chronic respiratory disease other than asthma or, diagnosed with another significant chronic disease, with possible interference with the objectives and/or evaluations of the study. * patients that participated in previous feasibility studies with inspirermundi app will be excluded.

Keywords: mhealth smartphone medication adherence self-management technology assessment
associations between chemotherapy-induced nausea in patients with genitourinary, sarcoma or melanoma cancers and changes in gut microbiome: potential for precision therapeutics

Conditions: Bladder Cancer; Prostate Cancer; Testicular Cancer; Bladder Carcinoma; Genitourinary System Carcinoma; Malignant Testicular Neoplasm; Melanoma; Prostate Carcinoma; Sarcoma

Summary: the objective of this pilot cohort study is to investigate associations between cin and changes in gut microbiome composition profiles.

the long-term goal of this study is to alleviate the occurrence of cin and to improve chemotherapy treatment outcomes. the identification of associations between cin and chemotherapy-induced changes in gut microbiome composition profiles will increase our understanding of these mechanisms that underlie cin. an increased understanding of the underlying mechanisms will provide targets for the development of novel interventions to help alleviate cin.

Eligibility criteria:
inclusion criteria: * at least 20 years of age * last chemotherapy more than 3 years ago * scheduled to receive either moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies) or immunotherapies/targeted therapies alone that can lead to toxicity symptoms for example, nausea and fatigue. * patients receiving chemotherapy and/or immunotherapy treatment at a mayo clinic infusion center or an infusion center outside of mayo clinic exclusion criteria: * concurrent radiation therapy * concurrent antibiotic treatment * concurrent oncolytic virus treatment